{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:00:55Z","timestamp":1791208855794,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J011586"],"award-info":[{"award-number":["2024J011586"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Provincial Administration of Traditional Chinese Medicine","award":["202620"],"award-info":[{"award-number":["202620"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-61750-w","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:05:03Z","timestamp":1783487103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FTO-mediated m6A modification alleviates diabetic nephropathy progression by downregulating the CYP2J3\/Smurf2 axis"],"prefix":"10.1038","volume":"16","author":[{"given":"Yinhao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"61750_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/a-2435-8264","volume":"57","author":"S Dwivedi","year":"2025","unstructured":"Dwivedi, S. & Sikarwar, M. S. Diabetic nephropathy pathogenesis, mechanisms, and therapeutic strategies. Horm. Metab. Res. 57, 7\u201317. https:\/\/doi.org\/10.1055\/a-2435-8264 (2025).","journal-title":"Horm. Metab. Res."},{"key":"61750_CR2","doi-asserted-by":"publisher","first-page":"1602594","DOI":"10.3389\/fendo.2025.1602594","volume":"16","author":"G Hou","year":"2025","unstructured":"Hou, G. et al. Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy. Front. Endocrinol. (Lausanne). 16, 1602594. https:\/\/doi.org\/10.3389\/fendo.2025.1602594 (2025).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"61750_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.tips.2025.07.014","volume":"47","author":"M Liu","year":"2026","unstructured":"Liu, M. et al. Beyond lipids: Fenofibrate in diabetic retinopathy and nephropathy. Trends Pharmacol. Sci. 47, 325\u2013341. https:\/\/doi.org\/10.1016\/j.tips.2025.07.014 (2026).","journal-title":"Trends Pharmacol. Sci."},{"key":"61750_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.endien.2022.01.007","volume":"69","author":"H Yang","year":"2022","unstructured":"Yang, H. et al. MiR-153-3p reduces extracellular matrix accumulation in high glucose-stimulated human glomerular mesangial cells via targeting PAQR3 in diabetic nephropathy. Endocrinol. Diabetes Nutr. (Engl Ed). 69, 34\u201342. https:\/\/doi.org\/10.1016\/j.endien.2022.01.007 (2022).","journal-title":"Endocrinol. Diabetes Nutr. (Engl Ed)"},{"key":"61750_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.freeradbiomed.2019.09.003","volume":"145","author":"S Qiao","year":"2019","unstructured":"Qiao, S. et al. Bergenin impedes the generation of extracellular matrix in glomerular mesangial cells and ameliorates diabetic nephropathy in mice by inhibiting oxidative stress via the mTOR\/\u03b2-TrcP\/Nrf2 pathway. Free Radic. Biol. Med. 145, 118\u2013135. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.09.003 (2019).","journal-title":"Free Radic Biol. Med."},{"key":"61750_CR6","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.3892\/mmr.2020.11486","volume":"22","author":"X Mou","year":"2020","unstructured":"Mou, X. et al. A novel identified circular RNA, circ_0000491, aggravates the extracellular matrix of diabetic nephropathy glomerular mesangial cells through suppressing miR-101b by targeting TGF\u03b2RI. Mol. Med. Rep. 22, 3785\u20133794. https:\/\/doi.org\/10.3892\/mmr.2020.11486 (2020).","journal-title":"Mol. Med. Rep."},{"key":"61750_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/dom.16069","volume":"27","author":"T Zheng","year":"2025","unstructured":"Zheng, T. et al. Integrative transcriptome analysis reveals Serpine2 promotes glomerular mesangial cell proliferation and extracellular matrix accumulation via activating ERK1\/2 signalling pathway in diabetic nephropathy. Diabetes Obes. Metab. 27, 750\u2013766. https:\/\/doi.org\/10.1111\/dom.16069 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"61750_CR8","doi-asserted-by":"publisher","first-page":"1607932","DOI":"10.3389\/fimmu.2025.1607932","volume":"16","author":"X Li","year":"2025","unstructured":"Li, X. et al. m6A modification: A novel mechanism that regulates atherosclerosis via macrophage polarization. Front. Immunol. 16, 1607932. https:\/\/doi.org\/10.3389\/fimmu.2025.1607932 (2025).","journal-title":"Front. Immunol."},{"key":"61750_CR9","doi-asserted-by":"publisher","first-page":"113759","DOI":"10.1016\/j.intimp.2024.113759","volume":"145","author":"T Hu","year":"2025","unstructured":"Hu, T. et al. m6A methylation modification: Potential pathways to suppress osteosarcoma metastasis. Int. Immunopharmacol. 145, 113759. https:\/\/doi.org\/10.1016\/j.intimp.2024.113759 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"61750_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12964-025-02254-4","volume":"23","author":"Y Han","year":"2025","unstructured":"Han, Y. et al. Biological roles of enhancer RNA m6A modification and its implications in cancer. Cell. Commun. Signal. 23, 254. https:\/\/doi.org\/10.1186\/s12964-025-02254-4 (2025).","journal-title":"Cell. Commun. Signal."},{"key":"61750_CR11","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s12276-024-01330-y","volume":"56","author":"H Zhou","year":"2024","unstructured":"Zhou, H. et al. FTO-mediated SMAD2 m6A modification protects cartilage against Osteoarthritis. Exp. Mol. Med. 56, 2283\u20132295. https:\/\/doi.org\/10.1038\/s12276-024-01330-y (2024).","journal-title":"Exp. Mol. Med."},{"key":"61750_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13578-025-01395-w","volume":"15","author":"C Zhou","year":"2025","unstructured":"Zhou, C. et al. FTO downregulation-mediated m6A modification resulting in enhanced hepatocellular carcinoma invasion. Cell. Biosci. 15, 58. https:\/\/doi.org\/10.1186\/s13578-025-01395-w (2025).","journal-title":"Cell. Biosci."},{"key":"61750_CR13","doi-asserted-by":"publisher","first-page":"142181","DOI":"10.1016\/j.ijbiomac.2025.142181","volume":"307","author":"Q Li","year":"2025","unstructured":"Li, Q. et al. FTO-mediated m6A modification elevates the MFN2 mRNA stability to suppress ovarian granulosa cell senescence. Int. J. Biol. Macromol. 307, 142181. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.142181 (2025).","journal-title":"Int. J. Biol. Macromol."},{"key":"61750_CR14","doi-asserted-by":"publisher","first-page":"123355","DOI":"10.1016\/j.lfs.2024.123355","volume":"363","author":"L Yan","year":"2025","unstructured":"Yan, L. & Guo, L. The role and mechanism of m6A methylation in diabetic nephropathy. Life Sci. 363, 123355. https:\/\/doi.org\/10.1016\/j.lfs.2024.123355 (2025).","journal-title":"Life Sci."},{"key":"61750_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12882-024-03741-5","volume":"25","author":"Q Li","year":"2024","unstructured":"Li, Q. & Mu, S. FTO mediates the diabetic kidney disease progression through regulating the m6A modification of NLRP3. BMC Nephrol. 25, 345. https:\/\/doi.org\/10.1186\/s12882-024-03741-5 (2024).","journal-title":"BMC Nephrol."},{"key":"61750_CR16","doi-asserted-by":"publisher","first-page":"e19940","DOI":"10.7717\/peerj.19940","volume":"13","author":"S Guo","year":"2025","unstructured":"Guo, S. et al. The role of N6-methyladenosine (m6A) RNA methylation modification in kidney diseases: From mechanism to therapeutic potential. PeerJ 13, e19940. https:\/\/doi.org\/10.7717\/peerj.19940 (2025).","journal-title":"PeerJ"},{"key":"61750_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2337\/db09-1241","volume":"59","author":"X Xu","year":"2010","unstructured":"Xu, X. et al. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db\/db mice. Diabetes 59, 997\u20131005. https:\/\/doi.org\/10.2337\/db09-1241 (2010).","journal-title":"Diabetes"},{"key":"61750_CR18","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/s41401-020-0428-0","volume":"41","author":"WT You","year":"2020","unstructured":"You, W. T. et al. Ophiopogonin D maintains Ca2\u2009+\u2009homeostasis in rat cardiomyocytes in vitro by upregulating CYP2J3\/EETs and suppressing ER stress. Acta Pharmacol. Sin. 41, 1622. https:\/\/doi.org\/10.1038\/s41401-020-0428-0 (2020).","journal-title":"Acta Pharmacol. Sin"},{"key":"61750_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.prostaglandins.2011.08.002","volume":"96","author":"D Sacerdoti","year":"2011","unstructured":"Sacerdoti, D. et al. 11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat. 96, 72\u201375. https:\/\/doi.org\/10.1016\/j.prostaglandins.2011.08.002 (2011).","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"61750_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fmolb.2020.00128","volume":"7","author":"Y Bai","year":"2020","unstructured":"Bai, Y. & Ying, Y. The post-translational modifications of Smurf2 in TGF-\u03b2 signaling. Front. Mol. Biosci. 7, 128. https:\/\/doi.org\/10.3389\/fmolb.2020.00128 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"61750_CR21","doi-asserted-by":"publisher","first-page":"101161CIRCRESAH","DOI":"10.1161\/CIRCRESAHA.122.320538","volume":"5","author":"C Ni","year":"2022","unstructured":"Ni, C. et al. Flavin containing monooxygenase 2 prevents cardiac fibrosis via CYP2J3-SMURF2 axis. Circ. Res. 5, 101161CIRCRESAHA122320538. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.320538 (2022).","journal-title":"Circ. Res."},{"key":"61750_CR22","doi-asserted-by":"publisher","first-page":"112292","DOI":"10.1016\/j.diabres.2025.112292","volume":"226","author":"ZA Wani","year":"2025","unstructured":"Wani, Z. A. et al. Biomarkers in diabetic nephropathy: A comprehensive review of their role in early detection and disease progression monitoring. Diabetes Res. Clin. Pract. 226, 112292. https:\/\/doi.org\/10.1016\/j.diabres.2025.112292 (2025).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"61750_CR23","doi-asserted-by":"publisher","first-page":"110712","DOI":"10.1016\/j.cellsig.2023.110712","volume":"108","author":"D Qiu","year":"2023","unstructured":"Qiu, D. et al. NQO1 alleviates renal fibrosis by inhibiting the TLR4\/NF-\u03baB and TGF-\u03b2\/Smad signaling pathways in diabetic nephropathy. Cell. Signal. 108, 110712. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110712 (2023).","journal-title":"Cell. Signal."},{"key":"61750_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3892\/mmr.2025.13487","volume":"31","author":"M Huang","year":"2025","unstructured":"Huang, M. et al. Apelin\/APJ alleviates diabetic nephropathy by improving glomerular endothelial cells dysfunction via SIRT3-KLF15. Mol. Med. Rep. 31, 122. https:\/\/doi.org\/10.3892\/mmr.2025.13487 (2025).","journal-title":"Mol. Med. Rep."},{"key":"61750_CR25","doi-asserted-by":"publisher","first-page":"1335495","DOI":"10.3389\/fendo.2025.1335495","volume":"16","author":"J Yue","year":"2025","unstructured":"Yue, J. et al. Acupuncture for diabetic nephropathy: Mechanisms, clinical evidence, and future perspectives. Front. Endocrinol. (Lausanne). 16, 1335495. https:\/\/doi.org\/10.3389\/fendo.2025.1335495 (2025).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"61750_CR26","doi-asserted-by":"publisher","first-page":"elae051","DOI":"10.1093\/bfgp\/elae051","volume":"24","author":"X Huang","year":"2025","unstructured":"Huang, X. et al. m6A RNA modification pathway: Orchestrating fibrotic mechanisms across multiple organs. Brief. Funct. Genomics. 24, elae051. https:\/\/doi.org\/10.1093\/bfgp\/elae051 (2025).","journal-title":"Brief. Funct. Genomics"},{"key":"61750_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/biom15050617","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. The role of N6-methyladenosine (m6A) RNA modification in the pathogenesis of Parkinson\u2019s disease. Biomolecules 15, 617. https:\/\/doi.org\/10.3390\/biom15050617 (2025).","journal-title":"Biomolecules"},{"key":"61750_CR28","doi-asserted-by":"publisher","first-page":"128356","DOI":"10.1016\/j.micres.2025.128356","volume":"302","author":"H Chen","year":"2026","unstructured":"Chen, H. et al. Crosstalk between the m6A modification and the gut microbiota in lipid metabolism. Microbiol. Res. 302, 128356. https:\/\/doi.org\/10.1016\/j.micres.2025.128356 (2026).","journal-title":"Microbiol. Res."},{"key":"61750_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1615\/CritRevEukaryotGeneExpr.2024054011","volume":"34","author":"Y Chen","year":"2024","unstructured":"Chen, Y. & Huang, J. FTO-mediated m6A modification of FTH1 inhibits ferroptosis of neurons in neonatal cerebral hypoxic ischemia. Crit. Rev. Eukaryot. Gene Expr. 34, 47\u201357. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2024054011 (2024).","journal-title":"Crit. Rev. Eukaryot. Gene Expr"},{"key":"61750_CR30","doi-asserted-by":"publisher","first-page":"e70332","DOI":"10.1096\/fj.202403014R","volume":"39","author":"S Zhu","year":"2025","unstructured":"Zhu, S. et al. m6A demethylase Fto inhibited macrophage activation and glycolysis in diabetic nephropathy via m6A\/Npas2\/Hif-1\u03b1 axis. FASEB J. 39, e70332. https:\/\/doi.org\/10.1096\/fj.202403014R (2025).","journal-title":"FASEB J."},{"key":"61750_CR31","doi-asserted-by":"publisher","first-page":"20221049","DOI":"10.1515\/biol-2022-1049","volume":"20","author":"X Li","year":"2025","unstructured":"Li, X. et al. FTO alleviated the diabetic nephropathy progression by regulating the N6-methyladenosine levels of DACT1. Open. Life Sci. 20, 20221049. https:\/\/doi.org\/10.1515\/biol-2022-1049 (2025).","journal-title":"Open. Life Sci."},{"key":"61750_CR32","doi-asserted-by":"publisher","first-page":"e71299","DOI":"10.1096\/fj.202502267R","volume":"39","author":"S Pan","year":"2025","unstructured":"Pan, S. et al. FTO modulates m6A RNA methylation of STC1 to regulate inflammation and oxidative stress in diabetic nephropathy. FASEB J. 39, e71299. https:\/\/doi.org\/10.1096\/fj.202502267R (2025).","journal-title":"FASEB J."},{"key":"61750_CR33","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1159\/000493500","volume":"49","author":"X Huang","year":"2018","unstructured":"Huang, X. et al. Ophiopogonin D reduces myocardial ischemia-reperfusion injury via upregulating CYP2J3\/EETs in rats. Cell. Physiol. Biochem. 49, 1646\u20131658. https:\/\/doi.org\/10.1159\/000493500 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"61750_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41419-019-1308-8","volume":"10","author":"JH Kim","year":"2019","unstructured":"Kim, J. H. et al. TTC3 contributes to TGF-\u03b21-induced epithelial-mesenchymal transition and myofibroblast differentiation, potentially through SMURF2 ubiquitylation and degradation. Cell. Death Dis. 10, 92. https:\/\/doi.org\/10.1038\/s41419-019-1308-8 (2019).","journal-title":"Cell. Death Dis."},{"key":"61750_CR35","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s13577-024-01062-1","volume":"37","author":"L Guo","year":"2024","unstructured":"Guo, L. et al. MicroRNA-322-5p targeting Smurf2 regulates the TGF-\u03b2\/Smad pathway to protect cardiac function and inhibit myocardial infarction. Hum. Cell. 37, 972\u2013985. https:\/\/doi.org\/10.1007\/s13577-024-01062-1 (2024).","journal-title":"Hum. Cell"},{"key":"61750_CR36","doi-asserted-by":"publisher","first-page":"112931","DOI":"10.1016\/j.biopha.2022.112931","volume":"149","author":"J Zou","year":"2022","unstructured":"Zou, J. et al. Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-\u03b2\/Smad. Biomed. Pharmacother. 149, 112931. https:\/\/doi.org\/10.1016\/j.biopha.2022.112931 (2022).","journal-title":"Biomed. Pharmacother"},{"key":"61750_CR37","doi-asserted-by":"publisher","first-page":"e70108","DOI":"10.1096\/fj.202401489R","volume":"38","author":"S Tang","year":"2024","unstructured":"Tang, S. et al. Paricalcitol ameliorates diabetic nephropathy by promoting EETs and M2 macrophage polarization and inhibiting inflammation by regulating VDR\/CYP2J2 axis. FASEB J. 38, e70108 (2024).","journal-title":"FASEB J."},{"key":"61750_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/TACG.S281502","volume":"13","author":"MS Habieb","year":"2020","unstructured":"Habieb, M. S. et al. The human genetic variants CYP2J2 rs2280275 and EPHX2 rs751141 and risk of diabetic nephropathy in Egyptian type 2 diabetic patients. Appl. Clin. Genet. 13, 165\u2013178 (2020).","journal-title":"Appl. Clin. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61750-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:12:35Z","timestamp":1791205955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61750-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61750"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61750-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were conducted in accordance with the Animal Use Protocol and were approved by the Ethics Committee of Zvast-bio Technology Co., Ltd. (No. 20250805). All animal experiments complied with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Besides, all animal experiments as in accordance with the ARRIVE guidelines.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30930"}}